Co-Diagnostics Inc (CODX)
NASDAQ:CODX

Co-Diagnostics Stock Price & Analysis

1,538 Followers

CODX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.76 - $10.90
Previous Close$2.99
Volume26.36K
Average Volume (3M)230.82K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$86.49M
Total Debt (Recent Filing)$418.82K
Price to Earnings (P/E)6.5
Beta0.94
Next EarningsApr 04, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)0.46
Shares Outstanding30,917,856
R-Squared0.00314
Standard Deviation0.58
10 Day Avg. Volume137,492
30 Day Avg. Volume230,819
Price to Book (P/B)1.04
Price to Sales (P/S)1.74
Price to Cash Flow (P/CF)6.50
P/FCF Ratio6.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Alpha0.08
Number of Analyst Covering1


Financials


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CODX FAQ

What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was $2.76 and its highest was $10.90 in the past 12 months.
    What is Co-Diagnostics’s market cap?
    Currently, no data Available
    When is Co-Diagnostics’s upcoming earnings report date?
    Co-Diagnostics’s upcoming earnings report date is Apr 04, 2023 which is in 125 days.
      How were Co-Diagnostics’s earnings last quarter?
      Co-Diagnostics released its earnings results on Nov 10, 2022. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.042 by $0.002.
        Is Co-Diagnostics overvalued?
        According to Wall Street analysts Co-Diagnostics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Co-Diagnostics pay dividends?
          Co-Diagnostics does not currently pay dividends.
          What is Co-Diagnostics’s EPS estimate?
          Co-Diagnostics’s EPS estimate is -$0.15.
            How many shares outstanding does Co-Diagnostics have?
            Co-Diagnostics has 30,917,856 shares outstanding.
              What happened to Co-Diagnostics’s price movement after its last earnings report?
              Co-Diagnostics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.042. Following the earnings report the stock price went up 5.491%.
                Which hedge fund is a major shareholder of Co-Diagnostics?
                Among the largest hedge funds holding Co-Diagnostics’s share is Hussman Strategic Advisors Inc. It holds Co-Diagnostics’s shares valued at 116K.

                  ---

                  Co-Diagnostics Stock Smart Score

                  2
                  Underperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -67.84%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  12.90%
                  Trailing 12-Months
                  Asset Growth
                  40.32%
                  Trailing 12-Months
                  The Co-Diagnostics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Co-Diagnostics Inc

                  Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company's products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Abbott Labs
                  Intuitive Surgical
                  Stryker
                  Becton Dickinson
                  Edwards Lifesciences

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis